Syros Pharmaceuticals Inc (NASDAQ:SYRS) insider Eric R. Olson sold 1,753 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $11.72, for a total transaction of $20,545.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Syros Pharmaceuticals stock opened at $11.93 on Friday. The firm has a market cap of $548.32 million, a price-to-earnings ratio of -6.66 and a beta of 1.63. The stock has a 50-day simple moving average of $10.05 and a 200-day simple moving average of $8.02. Syros Pharmaceuticals Inc has a 52-week low of $4.26 and a 52-week high of $12.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 6.35 and a quick ratio of 6.35.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $1.72 million. Syros Pharmaceuticals had a negative net margin of 1,950.42% and a negative return on equity of 84.15%. As a group, equities research analysts predict that Syros Pharmaceuticals Inc will post -1.62 earnings per share for the current year.
A number of large investors have recently modified their holdings of the stock. Bank of Montreal Can raised its holdings in Syros Pharmaceuticals by 44.6% during the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock valued at $30,000 after buying an additional 1,357 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Syros Pharmaceuticals by 10.0% in the 4th quarter. Bank of America Corp DE now owns 15,081 shares of the company’s stock valued at $104,000 after acquiring an additional 1,366 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Syros Pharmaceuticals by 4.8% in the 4th quarter. Alliancebernstein L.P. now owns 30,500 shares of the company’s stock worth $211,000 after purchasing an additional 1,400 shares during the last quarter. Citigroup Inc. boosted its position in Syros Pharmaceuticals by 23.4% during the first quarter. Citigroup Inc. now owns 12,627 shares of the company’s stock worth $75,000 after purchasing an additional 2,391 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Syros Pharmaceuticals by 4.8% during the first quarter. Bank of New York Mellon Corp now owns 116,764 shares of the company’s stock valued at $692,000 after purchasing an additional 5,401 shares during the last quarter. Hedge funds and other institutional investors own 98.23% of the company’s stock.
A number of analysts have recently issued reports on the company. Piper Sandler increased their target price on Syros Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, May 29th. BidaskClub raised Syros Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 26th. Oppenheimer started coverage on Syros Pharmaceuticals in a research note on Monday, June 1st. They set a “buy” rating and a $11.00 target price on the stock. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research report on Saturday, May 9th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $12.88.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Story: Understanding Analyst Recommendations
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.